Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$75,643.00-0.08%ETH$2,391.02-0.37%GOLD$4,305.30-1.87%OIL$101.95-0.47%
Smart Investors Daily
CH

OTC · CHGCY

Chugai Pharmaceutical Co., Ltd.

Healthcare · Drug Manufacturers - General

$20.54

Down-$0.24 (-1.15%)

Updated Sep 16, 2026, 11:06 PM

SID Score

6.1/10

Composite research score

Smart Money

46/100

Neutral

Market cap
89.03B
P/E ratio
35.25
Dividend yield
2.99%
52-week range
— – —
Volume
32.36K
Avg. volume
145.36K

Price performance

CHGCY price history

1M range · 0 trading sessions · Daily adjusted prices

CHGCY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest CHGCY news

The latest Smart Investors Daily articles mentioning CHGCY.

Stock researchCompany · Overview

CHGCY research

Overview

Company profile and research snapshot.

Company profile

CHUGAI PHARM UNSP/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
—
Implied upside
—
Analysts
20
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors

TOKYO, September 09, 2026--Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) today announced that Dr. Kunihiro Hattori (former Senior Fellow of Chugai), Dr. Takehisa Kitazawa (Deputy Head of Research Division, Chugai), and Dr. Tomoyuki Igawa (Head of Research Division, Chugai), who led the creation of Hemlibra (emicizumab), a treatment for hemophilia A, have been awarded the Lasker-DeBakey Clinical Medical Research Award, one of the world's most prestigious scientific honors.

Yahoo · Sep 2, 2026

Autoimmune Uveitis Market to Expand at a CAGR of 7% During the Forecast Period (2026-2036) as Novel Treatments Challenge the Existing Therapeutic Landscape | DelveInsight

Recently published Autoimmune Uveitis Market Insights report includes a comprehensive understanding of current treatment practices, autoimmune uveitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Yahoo · Aug 27, 2026

3 Japanese AI Healthcare Stocks Investors May Want To Watch

With governments such as China channeling fresh fiscal spending into healthcare and social security, artificial intelligence in medicine is moving from theory into real projects that need practical solutions. That creates a window for investors who want exposure to AI tools that may help clinicians, hospitals, and researchers work smarter. This article highlights three Transformative AI Healthcare stocks from our screener that show how this theme is taking shape. The three stocks below are a...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By